Inclusion criteria: ≥ 18 years of age, diagnosis of cirrhosis or chronic liver disease, diagnosis of SBP, and received ≥ 5 days of systemic antibiotics. Patients groups were compared to determine length of stay (LOS), development of hepatorenal syndrome (HRS), bleeding, hepatic encephalopathy (HE), and mortality. Results:Eighty patients were included with 44 patients in the SA group and 36 patients in the SA+R group. Overall mortality rate was 36%, with no statistically significant differences between the SA vs SA+R

group (38% vs 34%; p=NS). Average LOS was similar between the two groups (SA group 12.3±10.8 days vs SA+R group 14.8±13.7 days; p=NS). Comparison of the SA group vs SA+R group for differences in number of patients that developed HRS, bleeding, or HE did not reveal any statistically significant differences. However, 18 patients FDA approved Drug Library datasheet had documentation of rifaximin as a home medication prior to admission. Upon review of patients receiving rifaximin prior to admission vs those who did not, there was a statistically significant difference in the development of HRS (11% vs 40%; p=0.02). Conclusion:The addition of rifaximin to systemic antibiotics for inpatient treatment of SBP did not affect LOS nor did it alter Sirolimus datasheet the development

of HRS, bleeding, HE, or mortality. Conversely, receiving rifaximin prior to admission significantly reduced the progression to HRS. Larger prospective studies are needed to validate these results. Disclosures: Satheesh Nair – Advisory

Committees or Review Panels: Jansen; Speaking and Teaching: Gilead Sanjaya K. Satapathy – Advisory Committees or Review Panels: Gilead The following people have nothing to disclose: Jennifer D. Twilla, Anuj Sharma, Emily H. Wong BACKGROUND: Ascites is a common diagnosis in hospitalized children due to its association with a myriad of etiologies. Little is known about factors predictive of morbidity and mortality in this population. METHODS: IRB approved retrospective cross-sectional chart review was performed on children aged 0-21 hospitalized at Johns Hopkins Hospital between 1983-2010 with an ICD-9 diagnosis of ascites (789.5, 789.51, 789.59). Multiple regression analysis was used selleck chemicals llc to identify demographic, laboratory, and clinical features as potential predictors of morbidity and mortality. Study outcomes included hospital length of stay (LOS) as a proxy for morbidity and mortality (defined as death at hospital discharge). Predictors analyzed included demographic data, ascites etiology and grade (I, II or III), co-morbidities (hepatic encephalopathy (HE), hepatorenal syndrome (HRS), portal vein thrombosis, hydrotho-rax, etc.) and lab markers (thrombocytopenia, anemia, hyponatremia, and leukopenia). RESULTS: A total of 518 children were studied. The average LOS of the population was 23.6 days.